SANGAMO THERAPEUTICS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
SANGAMO THERAPEUTICS INC. - More news...
SANGAMO THERAPEUTICS INC. - More news...
- Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
- Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients
- Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
- Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
- European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation
- Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
- Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
- Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
- Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
- Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Sangamo Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
- Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
- Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
- Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
- Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
- Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
- Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
- Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference
- Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
- Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
- Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
- Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results
- Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
- Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast
- Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
- Sangamo Therapeutics Announces Participation at 2021 Wedbush PacGrow Healthcare Conference
- Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
- Sangamo Therapeutics Announces Second Quarter 2021 Conference Call and Webcast
- Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer
- Sangamo Therapeutics Announces Participation at Jefferies Healthcare Conference
